中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Drug-mediated inhibition of Fli-1 for the treatment of leukemia

文献类型:期刊论文

作者Li, Y-J; Zhao, X.; Vecchiarelli-Federico, L. M.1; Li, Y.; Datti, A.2,3; Cheng, Y.4; Ben-David, Y.1
刊名BLOOD CANCER JOURNAL
出版日期2012
卷号2页码:e54
关键词Erythroleukemia Fli-1 Drug Inhibition
ISSN号2044-5385
DOI10.1038/bcj.2011.52
通讯作者Ben-David, Y (reprint author), Univ Toronto, Dept Med Biophys, Sunnybrook Hlth Sci Ctr, Rm S216,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada, bendavid@sri.utoronto.ca
文献子类Article
英文摘要The Ets transcription factor, Fli-1 is activated in murine erythroleukemia and overexpressed in various human malignancies including Ewing's sarcoma, induced by the oncogenic fusion protein EWS/Fli-1. Recent studies by our group and others have demonstrated that Fli-1 plays a key role in tumorigenesis, and disrupting its oncogenic function may serve as a potential treatment option for malignancies associated with its overexpression. Herein, we describe the discovery of 30 anti-Fli-1 compounds, characterized into six functional groups. Treatment of murine and human leukemic cell lines with select compounds inhibits Fli-1 protein or mRNA expression, resulting in proliferation arrest and apoptosis. This anti-cancer effect was mediated, at least in part through direct inhibition of Fli-1 function, as anti-Fli-1 drug treatment inhibited Fli-1 DNA binding to target genes, such as SHIP-1 and gata-1, governing hematopoietic differentiation and proliferation. Furthermore, treatment with select Fli-1 inhibitors revealed a positive relationship between the loss of DNA-binding activity and Fli-1 phosphorylation. Accordingly, anti-Fli-1 drug treatment significantly inhibited leukemogenesis in a murine erythroleukemia model overexpressing Fli-1. This study demonstrates the ability of this drug-screening strategy to isolate effective anti-Fli-1 inhibitors and highlights their potential use for the treatment of malignancies overexpressing this oncogene.
WOS关键词FRIEND-ERYTHROLEUKEMIC CELLS ; TRANSCRIPTION FACTOR ; ERYTHROID PROLIFERATION ; CARDIAC-GLYCOSIDES ; EWING SARCOMA ; DIFFERENTIATION ; VIRUS ; GENE ; IDENTIFICATION ; TRANSLOCATION
WOS研究方向Oncology
语种英语
WOS记录号WOS:000300405300006
资助机构Ontario Institute for Cancer Research (OICR); Canadian Institute of Health Research (CIHR)[MOP-110952]
公开日期2012-06-07
源URL[http://ir.kib.ac.cn:8080/handle/151853/10393]  
专题昆明植物研究所_植物化学与西部植物资源持续利用国家重点实验室
作者单位1.Univ Toronto, Dept Med Biophys, Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
2.Mt Sinai Hosp, Samuel Lunenfeld Res Inst, SMART Facil, Toronto, ON M5G 1X5, Canada
3.Univ Perugia, Dept Expt Med & Biochem Sci, I-06100 Perugia, Italy
4.Chinese Acad Sci, Kunming Inst Bot, Kunming, Peoples R China
推荐引用方式
GB/T 7714
Li, Y-J,Zhao, X.,Vecchiarelli-Federico, L. M.,et al. Drug-mediated inhibition of Fli-1 for the treatment of leukemia[J]. BLOOD CANCER JOURNAL,2012,2:e54.
APA Li, Y-J.,Zhao, X..,Vecchiarelli-Federico, L. M..,Li, Y..,Datti, A..,...&Ben-David, Y..(2012).Drug-mediated inhibition of Fli-1 for the treatment of leukemia.BLOOD CANCER JOURNAL,2,e54.
MLA Li, Y-J,et al."Drug-mediated inhibition of Fli-1 for the treatment of leukemia".BLOOD CANCER JOURNAL 2(2012):e54.

入库方式: OAI收割

来源:昆明植物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。